Efficacy of Stromal Vascular Fraction on Acne Scar Correction

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jul 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for atrophic acne scars, which are the sunken or indented scars some people get after acne. The treatment involves injecting a special mixture of cells called stromal vascular fraction (SVF), taken from the patient’s own fat tissue, into the skin. These cells may help repair and regenerate the skin to improve the appearance of scars. To see if SVF really works, the study will compare the results of SVF injections on one side of the face with simple saline (saltwater) injections on the other side, which act as a placebo or control.

People who might be eligible for this study are adults between 19 and 45 years old who have atrophic acne scars on both sides of their face and are willing to have a small fat sample taken for the treatment. Participants will need to be healthy enough to attend follow-up visits and should not have active acne, recent scar treatments, or certain medical conditions that affect healing. During the study, participants will receive injections on both sides of their face and undergo evaluations like photos and skin assessments to check for improvements. This study is not yet recruiting, but it aims to find out if SVF injections are a safe and better option than current treatments for acne scars.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 19 and 45 years
• • Presence of bilateral atrophic acne scars (boxcar, rolling, or icepick types) on the face
• • Willingness to undergo fat harvesting procedure
• • Ability to comply with study visits and follow-up
• • Written informed consent obtained
• Exclusion Criteria:
• • Active acne lesions on the treatment area
• • History of keloid or hypertrophic scarring
• • Prior treatment for acne scars (e.g., laser, filler, microneedling) within the past 6 months
• • History of systemic immunosuppressive therapy within the past 3 months
• • Pregnant or breastfeeding women
• • Any systemic disease that may interfere with wound healing or safety assessment (e.g., uncontrolled diabetes, collagen vascular disease)